Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-сontrolled Comparative Study to Evaluate the Safety, Tolerability and Efficacy of XC221 Used at 100 mg Daily and at 200 mg Daily in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

NCT05030324 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT05030324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05030324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-сontrolled Comparative Study to Evaluate the Safety, Tolerability and Efficacy of XC221 Used at 100 mg Daily and at 200 mg Daily in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
Lead sponsor
Valenta Pharm JSC
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2021
Completion date
May 4, 2022
Enrollment
255 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute viral upper respiratory infections, influenza, viral respiratory infection